<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975650</url>
  </required_header>
  <id_info>
    <org_study_id>Nasobol-01-2009</org_study_id>
    <secondary_id>TBS1-01</secondary_id>
    <nct_id>NCT00975650</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of an Intra-Nasal Testosterone Product</brief_title>
  <official_title>Efficacy and Tolerability of Nasobol®, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is being performed to compare the pharmacokinetic profile of testosterone
      after repeated intra-nasal administration of products of different strengths in subjects with
      hypogonadism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      The primary objective of this study was to determine the efficacy of Nasobol in the treatment
      of hypogonadal men requiring testosterone replacement therapy. Efficacy was determined by
      establishing a pharmacokinetic profile for serum testosterone levels following Nasobol
      treatment, and comparing it to that of the active control, Androderm®.

      Secondary Objective:

      To establish a safety profile for Nasobol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Testosterone Ln-Cmax</measure>
    <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
    <description>The primary objective of this study was to determine the efficacy of Nasobol in the treatment of hypogonadal men requiring testosterone replacement therapy. Efficacy was determined by establishing a pharmacokinetic profile for serum testosterone levels following Nasobol treatment or that of the active control, Androderm®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Testosterone Ln-AUCt</measure>
    <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Testosterone Cavg</measure>
    <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Dihydrotestosterone Ln-Cmax</measure>
    <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Dihydrotestosterone Ln-AUCt</measure>
    <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Dihydrotestosterone Cavg</measure>
    <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Cavg Within the Reference Range</measure>
    <time_frame>Each period is 7 days</time_frame>
    <description>The percentage of subjects with a Cavg within the reference range of 300 to 1050 ng/dL and 25.5 to 97.8 ng/dL for testosterone and dihydotestosterone.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Test 8.0, Ref 5.0, Test 14.0, Test 11.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 11.0, Test 8.0, Ref 5.0, Test 14.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 14.0, Test 11.0, Test 8.0, Ref 5.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ref 5.0, Test 14.0, Test 11.0, Test 8.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nasobol®</intervention_name>
    <description>Intra-nasal Testosterone (2 syringes), b.i.d.</description>
    <arm_group_label>Ref 5.0, Test 14.0, Test 11.0, Test 8.0</arm_group_label>
    <arm_group_label>Test 11.0, Test 8.0, Ref 5.0, Test 14.0</arm_group_label>
    <arm_group_label>Test 14.0, Test 11.0, Test 8.0, Ref 5.0</arm_group_label>
    <arm_group_label>Test 8.0, Ref 5.0, Test 14.0, Test 11.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androderm® (Positive Control)</intervention_name>
    <description>QD administration</description>
    <arm_group_label>Ref 5.0, Test 14.0, Test 11.0, Test 8.0</arm_group_label>
    <arm_group_label>Test 11.0, Test 8.0, Ref 5.0, Test 14.0</arm_group_label>
    <arm_group_label>Test 14.0, Test 11.0, Test 8.0, Ref 5.0</arm_group_label>
    <arm_group_label>Test 8.0, Ref 5.0, Test 14.0, Test 11.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with primary or secondary hypogonadism and a serum morning (0900 h ± 30 minutes)
             testosterone levels &gt;100 ng/dl and ≤ 300 ng/dL.

          -  Normal Otolaryngological nasal endoscopy examination.

          -  Normal prostate examination (no palpable prostatic mass), and serum PSA ≤ 4.0 ng/mL.

        Exclusion Criteria:

          -  Current treatment with other androgens (i.e. DHEA), anabolic steroids or other sex
             hormones

          -  Treatment with Estrogens, GnRH antagonists, or Growth Hormone within previous 12
             months

          -  History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, or
             sinus surgery.

          -  History of nasal disorders (e.g. polyposis, recurrent epistaxis ( &gt; 1 nose bleed per
             month, abuse of nasal decongestants) or sleep apnea.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Desjardins, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Trimel Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quality of Life Medical &amp; Research centre</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <results_first_submitted>March 9, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2018</results_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Hypogonadism</keyword>
  <keyword>Secondary Hypogonadism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All Subjects who were dosed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Testosterone Ln-Cmax</title>
        <description>The primary objective of this study was to determine the efficacy of Nasobol in the treatment of hypogonadal men requiring testosterone replacement therapy. Efficacy was determined by establishing a pharmacokinetic profile for serum testosterone levels following Nasobol treatment or that of the active control, Androderm®.</description>
        <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone Ln-Cmax</title>
          <description>The primary objective of this study was to determine the efficacy of Nasobol in the treatment of hypogonadal men requiring testosterone replacement therapy. Efficacy was determined by establishing a pharmacokinetic profile for serum testosterone levels following Nasobol treatment or that of the active control, Androderm®.</description>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="0.37"/>
                    <measurement group_id="O2" value="6.41" spread="0.35"/>
                    <measurement group_id="O3" value="6.54" spread="0.36"/>
                    <measurement group_id="O4" value="6.36" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Testosterone Ln-AUCt</title>
        <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone Ln-AUCt</title>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>ng.h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.80" spread="0.26"/>
                    <measurement group_id="O2" value="8.90" spread="0.27"/>
                    <measurement group_id="O3" value="8.95" spread="0.29"/>
                    <measurement group_id="O4" value="9.09" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Testosterone Cavg</title>
        <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone Cavg</title>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.10" spread="76.42"/>
                    <measurement group_id="O2" value="316.64" spread="88.93"/>
                    <measurement group_id="O3" value="336.11" spread="100.76"/>
                    <measurement group_id="O4" value="384.62" spread="102.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Dihydrotestosterone Ln-Cmax</title>
        <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Dihydrotestosterone Ln-Cmax</title>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.38"/>
                    <measurement group_id="O2" value="3.67" spread="0.44"/>
                    <measurement group_id="O3" value="3.80" spread="0.41"/>
                    <measurement group_id="O4" value="3.44" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Dihydrotestosterone Ln-AUCt</title>
        <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Dihydrotestosterone Ln-AUCt</title>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>ng.h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" spread="0.38"/>
                    <measurement group_id="O2" value="6.47" spread="0.41"/>
                    <measurement group_id="O3" value="6.52" spread="0.45"/>
                    <measurement group_id="O4" value="6.33" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Dihydrotestosterone Cavg</title>
        <time_frame>0.0 (trough), 0.50, 1.0, 1.5, 2.0, 3.0, 6.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0, 13.0, 16.0, 19.0, 22.0, and 24.0 hours.</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Dihydrotestosterone Cavg</title>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.24" spread="8.51"/>
                    <measurement group_id="O2" value="28.97" spread="11.41"/>
                    <measurement group_id="O3" value="30.79" spread="12.50"/>
                    <measurement group_id="O4" value="24.69" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Cavg Within the Reference Range</title>
        <description>The percentage of subjects with a Cavg within the reference range of 300 to 1050 ng/dL and 25.5 to 97.8 ng/dL for testosterone and dihydotestosterone.</description>
        <time_frame>Each period is 7 days</time_frame>
        <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Cavg Within the Reference Range</title>
          <description>The percentage of subjects with a Cavg within the reference range of 300 to 1050 ng/dL and 25.5 to 97.8 ng/dL for testosterone and dihydotestosterone.</description>
          <population>Number of participants includes participants who completed the corresponding treatment and had sufficient plasma concentration data to calculate the PK parameter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dihydrotestosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nathan Bryson, Vice President, Scientific Affairs</name_or_title>
      <organization>Acerus Pharmaceuticals Corporation</organization>
      <phone>1-416-679-0776</phone>
      <email>nbryson@aceruspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

